Yither Bio

Yither Bio is a biotechnology company specializing in the discovery and development of next-generation molecular glue degraders to treat cancer and other serious diseases. Utilizing its proprietary Y-Glue platform, the company focuses on targeting "undruggable" proteins by facilitating their degradation through the cellular ubiquitin-proteasome system. The platform integrates high-throughput screening, structural biology, and AI-driven design to identify novel small molecules that induce proximity between E3 ligases and target proteins. Yither Bio aims to expand the scope of targeted protein degradation beyond traditional PROTACs, offering potential for improved oral bioavailability and broader tissue distribution. The company is headquartered in Shanghai and is backed by prominent life science investors.